Interleukin-11 (IL-11) decreases cytokine release and increases survival in murine BMT models. In these systems, it reduces gut permeability, partially polarizes T cells to a Th2 phenotype, down-regulates IL-12, prevents mucositis, and accelerates recovery of oral and bowel mucosa. We conducted a randomized doubleblind pilot study of rhIL-11 administered with cyclosporine/MTX prophylaxis after cytoxan/TBI conditioning and allogeneic stem cell transplantation for hematologic malignancies. Patients received rhIL-11, 50 g/kg subcutaneously daily or placebo in a 3:1 ratio. Treatment was administered prior to the start of conditioning and continued up to 21 days. The study was designed to assess safety with stopping rules for cardiac arrhythmias and mortality. Although projected to accrue 20 patients, only 13 patients (10 IL-11, three placebo) were enrolled because the early stopping rule for mortality was triggered. Of 10 evaluable patients who received IL-11, four died by day 40 and one died on day 85. Deaths were attributable to transplant-related toxicity. One of three placebo recipients died of suicide, the other two are alive. Patients receiving IL-11 had severe fluid retention and early mortality, making it impossible to determine whether IL-11 given in this schedule can reduce the rate of GVHD. Grade B-D acute GVHD occurred in two of eight evaluable patients on IL-11 and one of three patients on placebo. The primary adverse events of the study were severe fluid retention resistant to diuresis (average weight gain 9 ± 4%) and multiorgan failure in five of 10 evaluable patients. The use of IL-11 as GVHD prophylaxis in allogeneic transplantation cannot be recommended as administered in this trial.
GVHD is a major limitation in the successful use of stem cell transplantation for hematologic diseases. Increasing evidence supports the concept that inflammatory cytokines are critical in the initiation and maintenance of acute graftversus-host disease (GVHD). One contributor to the induction of GVHD is mucosal injury to the digestive tract that can result in leakage of endotoxin into the body. Naive T cells from the donor are introduced into a milieu that fosters inflammation, where they are activated by cytokines, and where they recognize minor histocompatibility antigens in conjunction with HLA on recipient antigen presenting cells. The resulting expansion of allo-reactive T cells is facilitated by the pro-inflammatory milieu. End organ damage then results from the combined effects of primary cytokineinduced injury and direct cellular cytotoxicity. Endotoxin (LPS) contributes to this effect by enhancing the production of these inflammatory mediators. The cytokines that have been previously implicated include TNF-␣, IL-1, IL-12, IFN-␥. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Finally, cytokines and their inhibitors affect the polarization of T cells. Th1 cells that produce IL-2 and IFN-␥ tend to be associated with GVHD, while Th2 cell predominance tends to diminish the risk of GVHD. Thus, manipulations that foster Th2 polarization may reduce the likelihood of acute GVHD. 13 Transplant-related morbidity and mortality are substantially linked to several inter-related factors that could be directly ameliorated by IL-11. If IL-11 can result in reductions in gut permeability, polarization of T cells to the Th2 phenotype, and down-regulation of IL-12, it may substantially ameliorate GVHD. Mucositis is a serious transplant-related morbidity. More than 90% of patients develop grade 4 mucositis as manifested by severe erosive mucosal damage and the requirement for parenteral narcotics. It is intrinsically valuable to reduce mucositis for patient comfort; however, it may contribute to a reduction in GVHD directly by improving barrier function and reduce the risk of intestinal hemorrhage and infection by maintaining intestinal integrity. [14] [15] [16] [17] To determine whether these effects would translate into improved outcome after human transplantation, we conducted a randomized, double-blind pilot study of rhIL-11 administered with standard cyclosporine/MTX prophylaxis after cytoxan/TBI conditioning for hematologic malignancies.
Patients, materials, and methods
The trial was a double blind, randomized, placebocontrolled study of marrow transplantation in patients with hematologic malignancies. Patients were eligible if they were more than 18 years of age with satisfactory renal and hepatic function, had a histocompatible or one antigen mismatched family member or unrelated donor. Compatibility was determined serologically for class I and using standard molecular techniques for class II. A single unrelated donor was mismatched at HLA-C; all other patients were fully histocompatible. Enrollment took place between February and September 1999. All patients received bone marrow stem cells. Patient characteristics are shown in Table 1 . The study was designed as a pilot, safety trial with stopping rules for refractory arrhythmias and early mortality by day 40. The secondary objectives were to assess the effects of rhIL-11 on oral mucositis, grade B-D acute GVHD, 18 time to neutrophil recovery to Ͼ500 PMN/ml (defined as the first of 3 consecutive days of an absolute neutrophil count of у500 cells/l), number of platelet transfusions and time to transfusion independence, and survival at 100 days after the transplant. Voluntary informed consent was obtained on all patients. The institutional review boards of Dana-Farber Cancer Institute approved the study.
All patients received cyclophosphamide 1800 mg/m 2 on 2 consecutive days followed by total body irradiation, 14 Gy in eight fractions. Cyclosporine was administered beginning on day −3 at 2.5 mg/kg intravenously every 12 h. Methotrexate was given at a dose of 15 mg/m 2 on day +1 and at a dose of 10 mg/m 2 on days +3, +6 and +11. Study drug consisted of either recombinant human IL-11 (Oprelvekin, provided by Genetics Institute, Boston, MA, USA) administered subcutaneously at 50 g/kg per day for 21 days beginning the evening before the first cyclophos- a Individual ages are noted in the placebo group because of the small number of subjects.
phamide infusion or saline placebo given on the same schedule. The dose is the standard dose recommended by the manufacturer. It was administered before the start of conditioning based on data from animal models. 14, 15 The IL-11 is a clear, colorless solution with no infusional toxicities making it indistinguishable from placebo. All patients were treated in HEPA environments in reverse isolation using gut decontamination and acyclovir prophylaxis. Upon engraftment, all patients received P. carinii prophylaxis and CMV prophylaxis if clinically indicated.
Graft-versus-host disease and toxicity evaluation
Acute GVHD was graded and scored according to the consensus grading system 19 and IBMTR grading scale, although the primary endpoint was the IBMTR scale. 18 Mucositis was independently evaluated daily by the BMT attending physician and by the dental service every 3-4 days. Mucositis was scored according to the NCI standardized template: grade 0 = clear, no lesions; grade 1 = erythema at one site; grade 2 = erythema, one ulcerative site, and pain; grade 3 = two or more ulcerative sites; grade 4 = three or more ulcerative sites; grade 5 = ulcers covering the entire mouth. Mucositis scores for both ulceration and erythema for the same eight anatomical sites in each patient were totalled for each day of assessment in order to obtain 'total daily erythema scores' and 'total daily ulceration scores' per patient. The total daily ulceration scores and total daily erythema scores were then combined to obtain a 'total daily mucositis score' for each patient for each day of assessment. The 'average daily mucositis score per patient' was obtained by totalling each 'total daily mucositis score' for each patient, and dividing by the number of days that the patient was assessed. 20 Chronic GVHD was graded according to established criteria. 21 
Statistical considerations
The trial was a double blind, randomized, placebo-controlled study of patients with hematologic malignancies. The study was initially targeted toward patients with myelodysplasia, but generalized to all hematologic malignancies to enhance accrual. The study was designed as a pilot, safety trial with stopping rules for refractory arrhythmias and early mortality by day 40. The historical death rate at day 40 in a similar cohort of patients at this institution was 17%. The study was stopped when the lower boundary of the 90% confidence interval exceeded 17%. The secondary objectives were to assess the effects of rhIL-11 on oral mucositis, grade B-D acute GVHD, time to neutrophil recovery to Ͼ500 PMN/ml, number of platelet transfusions and time to transfusion independence, and survival at 100 days after the transplant. Patients were randomized in a 3:1 ratio to facilitate safety assessments.
Results
Although projected to accrue 20 patients, only 13 patients were enrolled because the early stopping rule was triggered. Ten patients received rhIL-11 and three received placebo.
One patient was taken off study after a single dose because of severe liver function test changes and is considered evaluable for safety but not efficacy endpoints. Her conditioning and transplantation began after she recovered from the hepatitis. In the IL-11 group, 5/9 received the whole 21 day course. In each case where the whole course was not administered, it was stopped due to toxicity. In the placebo group, two patients received study medication for 21 days and one patient received a 20 day course. One patient in the IL-11 group died on day 18 but the drug was stopped on day 16.
Blood count recovery
Median time to an absolute neutrophil count Ͼ500 cells/l in 11 evaluable patients was 22 days (range 16-28 days). Median time to last platelet transfusion in eight evaluable patients was 21 days (range 12-44 days). The control group was too small for a comparative analysis.
GVHD disease
Acute GVHD was observed in two of eight (25%) evaluable patients on rhIL-11 compared with one of three (33%) patients on placebo. The overall risk of acute GVHD in this study was three of 11 patients or 27%. The two patients on rhIL-11 had grade B and D GVHD. The one patient on placebo had grade B GVHD. All of the patients on study responded to therapy with corticosteroids. Chronic GVHD was observed in two of four patients (50%) surviving past day 100 in the IL-11 group.
Effect on mucositis
There was no apparent improvement in the degree of mucositis, oral intake, or average mouth pain scores in the patients receiving rhIL-11. Mucositis score (mean ± s.d.) was 5.5 ± 3.0 in the IL-11 recipients and 2.2 ± 1.0 in the placebo recipients.
Primary adverse events and survival
Severe fluid retention was observed in all patients (average weight gain 9 ± 4%), and it was resistant to diuresis. There was clinical evidence of hepatic veno-occlusive disease in one patient confirmed at postmortem examination. Fluid retention was treated with furosemide and fluid restriction when appropriate, but was usually refractory to management. One patient received a single dose of rhIL-11 and within 1 day had a 58-fold increase in AST, a 68-fold increase in ALT, doubling of the alkaline phosphatase, and four-fold increase in total bilirubin. The liver function tests returned to normal over the course of 1 week. She subsequently underwent transplantation off study and did well. No clear cause for the liver dysfunction was identified. Of 10 patients who received IL-11 and are evaluable for safety endpoints, four died by day 40. One additional patient died Bone Marrow Transplantation on day 85. The 1-year survival of the nine patients treated with IL-11 was 44%. Causes of death included sepsis (n = 1), uncal herniation and intracranial hemorrhage (n = 1), multiorgan failure (n = 1), alveolar hemorrhage (n = 2), and one late death (day 85) from interstitial pneumonia. One of three placebo recipients died of suicide (day 38), and the other two are alive at 570+ and 725+ days.
Discussion
We hypothesized that IL-11 would reduce the risk of GVHD and improve transplant-related mortality by several mechanisms. Prior work has identified well-defined models of GVHD that can be used to understand human GVHD pathophysiology. These models predict that TNF and IL-1 are major mediators of GVHD, and that much of the cytokine induction can be related to conditioning regimeninduced injury to the gut and subsequent leakage of endotoxin (LPS) into the circulation. Interventions that improve intestinal integrity, reduce LPS exposure, or alter cytokine response can all be expected to influence the risk of GVHD. In a MHC mismatched murine GVHD model that employs doses of total body X-irradiation that are similar to those used clinically, there is 70% mortality at day 10 in control animals. However, if the animals were pretreated for 2 days with IL-11 followed by 7-10 days of IL-11 therapy, mortality was Ͻ10% and was identical to that observed in syngeneic controls. Further analysis showed that this reduction in mortality is associated with (1) a reduction in systemic TNF and LPS levels, (2) protection of gut epithelium, (3) Th2 polarization of donor cells, (4) reduced IL-12 production, and (5) reduction in clinical GVHD grade. 17 Thus, IL-11 can be considered an indirect cytokine inhibitor in contrast to interleukin-1 receptor antagonist, soluble TNF receptor, soluble IL-1 receptor, or monoclonal antibodies that are direct cytokine inhibitors. IL-11 also has direct effects on gut mucosa. It appears to cause transient growth arrest by suppressing retinoblastoma gene phosphorylation, which delays entry into S phase. 22 Moreover, other investigators have shown that IL-11 protects mucosa from the effects of chemotherapy and irradiation and fosters its regeneration. There is increased stem cell proliferation in the base of the crypts, prolongation of villi, and enhancement of mucosal regeneration. This improves the survival of experimental animals subjected to a variety of injuries. [23] [24] [25] [26] [27] Furthermore, in a well-established hamster model of oral mucositis, the animals are protected from severe mucositis with either topical IL-11 or systemic IL-11, although systemic administration of IL-11 is much more effective. 28, 29 Mucositis is one of the primary morbidities of marrow transplantation and its severity also correlates with the development of blood-borne fungal and bacterial infections. 30 Despite the strong rationale for a salutary role of IL-11 in allogeneic transplantation based on murine studies, we observed that patients receiving rhIL-11 had immediate toxicity consisting of severe fluid retention requiring diligent fluid management. This was a predictable complication since fluid retention is a known toxicity of this drug that appears to be related to reduced sodium excretion. 31, 32 RhIL-11 has been given safely after autologous transplantation, but in the prior study it was given 8 days after the completion of stem cell infusion. 31 It is not clear whether the different schedule or the use in allogeneic transplantation accounts for the difference in outcome we observed. Unfortunately, IL-11 was also associated with excessive early mortality, making it impossible to determine whether rhIL-11 given in this schedule can reduce the rate of GVHD. We also observed no obvious improvement in neutrophil or platelet recovery. It is possible that in association with a different conditioning regimen or on a different schedule that benefits will be observed, but based on our data, the use of rhIL-11 as GVHD prophylaxis in allogeneic transplantation cannot be recommended as administered in this trial.
